


The Year 2018 in Review



Announcement of management change

Siegfried announced the withdrawal of Dr. Rudolf Hako as Chief Executive Officer of the Siegfried Group at year end. Dr. Wolfgang Wienand was appointed CEO of the Siegfried Group with effect from 1 January 2019.

Siegfried acquired production facility of Arena Pharmaceuticals GmbH in Zofingen

With effect from 1 April 2018, the Siegfried Group acquired the production facility for finished dosage forms (tablets and capsules) including the entire workforce and business contracts of Arena Pharmaceuticals GmbH in Zofingen.



377.2 million CHF

Publication of half-year results
The Siegfried Group reports net sales growth of 8.0 percent for the first half of 2018 while EBITDA grew by 20.1 percent to 63.5 million francs.



Siegfried appoints new Chief Scientific Officer

Dr. Jürgen Roos was appointed new Chief Scientific Officer. He will take on responsibility for Siegfried's research and development activities as a member of the Executive Committee with effect from 1 April 2019. In this function he succeeds Dr. Wolfgang Wienand, who was appointed Chief Executive Officer with effect from 1 January 2019 with overall responsibility for the company.

794.3 million CHF

Net sales
31 December 2018

750.5 million CHF

Publication of 2018 annual results
The Siegfried Group reported sales and margin growth for 2017.

New packaging and warehouse building in Irvine

Owing to production expansion, a new building was inaugurated in Irvine to provide urgently required space for storage of new products.

First GMP inspection by the Chinese FDA in Nantong

Swissmedic inspection in Evionnaz

Inspection by the Brazilian health authority (ANVISA) in Hameln

US FDA inspection in Pennsville

US FDA inspection in Hameln

US FDA inspection in Malta

US FDA inspection in St. Vulbas

GMP inspection by the Chinese FDA in Nantong

New production building in St. Vulbas

The cornerstone for the construction of a new production building in St. Vulbas was set.

New logistics center in Zofingen

A new logistics center was taken into operation in Zofingen. The new location on the edge of the site in close vicinity to production facilities improves efficiency.

40 new laboratory workplaces in Zofingen

The laboratory building in Zofingen was extended by the addition of 40 new laboratory workplaces. This reflects the increasing demand for research and development capacity by the entire Group.

Swissmedic inspection in Zofingen

US FDA inspection in Pennsville

GMP inspection by the German health authority (GAA) in Hameln